+44 (0) 1223 755950
+1 832 327 7413
Lirilumab
REQUEST MORE INFO
Catalogue No: abx831254
Price:
US$464.00
(Size: 100 µg)
Reviews: 
(0 Publications and Reviews)
(0 Publications and Reviews)
Click on the image to see the image legend
Lirilumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting KIRD2 subgroup, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications. Lirilumab has been used in trials studying the treatment of Leukemia, CANCER, NOS, Multiple Myeloma, Lymphocytic Leukemia, and Acute Myeloid Leukemia, among others.
Research Articles on KIRD2 subgroup
| Target | KIRD2 subgroup |
| Clonality | Monoclonal |
| Reactivity | Human |
| Expression | Recombinant |
| Tested Applications | ELISA, WB |
| Host | Human |
| Recommended dilutions | Optimal dilutions/concentrations should be determined by the end user. |
| Conjugation | Unconjugated |
| Isotype | IgG1 |
| Form | Liquid |
| Purity | > 95% |
| Purification | Purified from cell culture supernatants by Protein A/G chromatography. |
| Storage | Aliquot and store at -20°C. Avoid repeated freeze/thaw cycles. |
| Buffer | 0.01 M PBS. pH 7.4. |
| CAS Number | 1000676-41-4 |
| Concentration | Batch-dependent, typically between 0.5-2.0 mg/ml. |
| Availability | Shipped within 7-12 working days. |
| Note | This product is for research use only. Not for human consumption, cosmetic, therapeutic or diagnostic use. |